Peers of ARS Pharmaceuticals Inc (SPRY)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month revenue. A capital-structure-neutral sales valuation metric.
Latest EV/Sales
3.21x
As of Oct 9, 2026
Beyond EV/Sales, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/Sales |
|---|---|
| Oct 9, 2026 | 3.21x |
| Oct 8, 2026 | 3.47x |
| Oct 7, 2026 | 3.30x |
| Oct 6, 2026 | 3.25x |
| Oct 5, 2026 | 3.24x |
| Oct 2, 2026 | 3.06x |
| Oct 1, 2026 | 3.10x |
| Sep 30, 2026 | 3.26x |
EV/Sales = Enterprise Value / Revenue (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/Sales is particularly useful in M&A analysis and for companies with significant debt.
Read the general EV/Sales definition, formula, and analyst usage guide.
EV/Sales guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison